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1. Introduction 
Human immunodeficiency virus type 1 (HIV-1) infection is still a formidable threat to public 
health in spite of remarkable therapeutic advances (Adoga et al., 2009; Goselle, 2011). Highly 
active antiretroviral therapy (HAART) is effective against HIV/AIDS but it is not curative, 
and hence does not lead to the eradication of HIV-1 infection. Patients on HAART usually 
have their HIV RNA levels suppressed below the lower detection limit of 50 copies / ml. 
However, interruption of treatment leads to viral rebound and HIV can be detected again 
usually within two weeks (Davey et al.,1999; Dahl et al., 2010). This observation led to the 
initial questions that spurred investigations into the discovery of the critical roles of 
reservoirs and latency in HIV-1 persistence.  
Scientists continue to demonstrate that the major barriers to HIV/AIDS cure are the latently 
infected CD4+ T lymphocytes harbouring replication-competent HIV in lymph nodes, 
spleen and cells of the CNS (Cordelier, 2006; Dinoso et al., 2009). HIV-infected patients 
harbour  ~ 105 to 106 memory CD4 T-cells that contain fully integrated but transcriptionally 
silent HIV proviruses, which constitute a reservoir of viruses that show no sensitivity to 
highly active antiretroviral therapy (HAART), leading to HIV persistence in patients for life 
(Williams and Greene, 2007). 
Latently infected cells may be defined as transcriptionally silent cells that contain integrated 
HIV DNA, but which are capable of producing infectious virus only upon activation (Lassen 
et al., 2006; Pace et al., 2011). Based on this definition, it may be deduced that latently 
infected cells do not transcribe HIV RNA or express HIV proteins. On the contrary, it has 
been reported that resting CD4+ T cells and PBMC (peripheral blood mononuclear cell) 
from patients taking HAART do contain low levels of HIV RNA (Li et al., 2005; Fischer et al., 
2008; Pasternak et al., 2009). However, the low levels of HIV RNA are lower  than in 
activated CD4+ T cells, which brings to question as to whether the low levels of HIV RNA is 
enough for significant expression of protein (Lassen et al., 2004a; Zhang et al., 2004). 
Current evidence suggests that HAART suppresses viremia to below clinically detectable 
limit (50 HIV-1 RNA copies/ml) (Dinoso et al., 2009). It has been reported earlier that 
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antiretroviral drugs caused increase in CD4+ T cell counts and exponential decay in viremia, 
demonstrating the short lifespan of plasma virus with half life of about 2 days (Wei et al., 
1995; Perelson et al., 1996).This led to the earlier idea that, with prolonged use of 
combination antiretroviral drugs, HIV-1 could be eradicated completely leading to a cure 
(Perelson et al., 1997). However, we now know that mere prolonged use of HAART cannot 
cure HIV/AIDS because HIV-1 is capable of persisting in latently infected resting CD4+ T 
cells which constitute a reservoir for the virus (Rong and Perelson, 2009; Jochmans et al., 
2010; Margolis, 2010). 
This leads to the clear challenge of eliminating the virus in reservoirs or sanctuaries before a 
cure, hence prompting scientists in this field to devise various strategies or models of 
purging and eliminating the virus from the reservoir. In this chapter, we discussed HIV-1 
persistence and latency, the mechanisms for HIV latency, dynamics of persistent viremia, 
dynamics of viral decay, and current approaches for purging latent HIV reservoirs inter alia. 
2. Defining HIV-1 reservoir 
A cell type or anatomical site where a replication-competent form of a virus persists for a 
longer time than in the main pool of actively replicating virus can be termed a viral 
reservoir. In the case of HIV-1, CD4+ T-cells serve as major reservoirs both during HAART 
and untreated infection. The ultimate goal of HIV therapeutic interventions is to eradicate 
HIV-1 from persons infected with the virus. The development of potent antiretroviral 
regimens that greatly suppress HIV-1 replication has witnessed important life-saving 
advancement.  
Despite these therapeutic advances, major obstacles remain to eradicating HIV-1. Reservoirs 
of HIV-1 have been identified that represent major impediments to eradication. 
Conceptually, there are 2 types of sanctuaries or reservoirs for HIV-1, cellular and 
anatomical. Cellular sanctuaries or reservoirs may include latent CD4+ T cells containing 
integrated HIV-1 provirus; macrophages, which may express HIV-1 for prolonged periods; 
and follicular dendritic cells, which may hold infectious HIV-1 on their surfaces for 
indeterminate lengths of time. HIV-1 infected patients harbor ~ 105 - 106 memory CD4+ T 
cells that contain fully integrated but transcriptionally silent HIV proviruses. The key 
anatomical reservoir for HIV-1 appears to be the central nervous system. Critical clues for 
HIV-1 eradication lie in the understanding of the dynamics of HIV-1 within these reservoirs 
(Schrager & D’Souza, 1998; Williams & Greene, 2007).  
2.1 Resting CD4+ T cells are the main contributors to the reservoir 
The description of latently infected resting CD4+ T cells was first done by Chun and his 
colleagues (Chun et al., 1995). Latently infected CD4+ T cells are resting CD4+ T cells that 
lack activation markers including CD25, HLA-DR and CD69. Resting CD4+ T cells are in the 
G0/1a stage of the cell cycle, express limited levels of the transcription factors NFAT and 
NF-κβ, and have limited pools of deoxynucleosides, which are important for the efficient 
expression of the HIV LTR. Besides, resting CD4+ T cells have been shown to be enriched 
for microRNAs involved in HIV latency (Han et al., 2007; Huang et al., 2007; Colin & Van 
Lint, 2009; Margolis, 2010). In addition, studies have shown that during acute infection 
when reservoir establishes, the most prominently infected cell types are the resting CD4+ T 
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cells; and CD4+ T cells are the most frequently infected before or during HAART. An in 
vitro study with enhanced HIV-1 integration assay has also reported that HIV-1 integrates 
into resting CD4+ T cells even at low viral inoculum, suggesting that there is no threshold 
number of virions required for integration into resting CD4+ T cells (Schacker et al., 2000; Li 
et al., 2005; Agosto et al., 2007). Figure 1 illustrates dynamic patterns of the infection of 
CD4+ T cells. 
 
Fig. 1. Dynamics of HIV-I Infection of CD4+ T lymphocytes: The horizontal arrows show the 
successive steps in the life cycle of the virus; while the vertical arrows show the transitions 
between resting (small) and activated (large) CD4+ T cells. X4 isolates of HIV-1 can infect 
resting and activated CD4+ T cells, but replication does not occur in resting cells due to a 
block prior to the stage of nuclear import of the pre-integration complex containing the 
reverse-transcribed HIV-1 DNA. R5 isolates can infect activated CD4+ T cells, but may infect 
only the subset of resting CD4+ T cells that express sufficient amounts of CCR5 (Finzi & 
Siliciano, 1998). 
3. Dynamics of HIV-1 infection, decay characteristics and latency 
The dynamics of viral replication in vivo offer the best context to consider the 
pathophysiology of HIV-1 infection and the mechanisms of viral persistence. 
Understanding viral dynamics requires a steady state (in which continuous virus 
production is balanced by virus clearance) analysis of the amount of free virus and the 
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number of virally infected cells present in infected individuals (the viral load) and a 
dynamic analysis of the rates at which virus particles and virally infected cells are generated 
and cleared. Substantial progress has been made in understanding key elements of HIV-1 
dynamics, and the perspectives developed have already proven useful in understanding the 
pathogenesis of other infectious diseases.  
Several studies have described the dynamics of HIV-1 infection, decay characteristics and 
latency. In one of such studies, Perelson and colleagues used a set of differential equations 
and described the dynamics of cell infection and virion production and by fitting the decay 
data to the derived model. This way they were able to examine plasma viral levels early 
after the initiation of therapy in an effort to measure separately the two processes that 
contribute to the rapid initial decay of the plasma virus: the clearance of free virions and the 
loss of the infected cells that produce most of the plasma virus. They found out that 
corresponding half life  (t1/2) values for free virions ranged from 0.18 to 0.34 days , with a 
mean of 0.24 ± 0.06 days (~ 6 hours).  
Total daily virion production and clearance rates range from 0.4 x 109 to 32.1 x 109 virions 
per day, with a mean of 10.3 x 109 virions per day released into the extracellular fluid. The 
average life span of a virion in the extracellular phase is 0.3 ± 0.1 days, while the average life 
span of a productively infected cell (presumably an activated CD4+ T cell) is 2.2 ± 0.8 days. 
Productively infected CD4+ T cells are lost with with an average t ½ of about 1.6 days. The 
average life span of a virion in blood was calculated to be 0.3 days. Therefore a population 
of plasma virions is cleared with a  t ½ of 0.24 days. This  implies that, on the average, half of 
the population of plasma virions turns over in about every 6 hours. The average generation 
time of HIV-1, defined as the time from the release of a virion until it infects another cell and 
causes the release of a new generation of viral particles, was determined to be 2.6 days 
(Perelson et al., 1996; Finzi & Siliciano, 1998; Pierson et al., 2000; Dahl et al., 2010).  
4. How HIV-1 reservoirs are formed 
Several mechanisms may be involved in the formation of reservoirs. One mechanism is the 
direct infection of resting CD4+ T cells. This is supported by the fact that resting cells are the 
prominently infected cells during early infection (Li et al., 2005). Still in support of this 
mechanism, data from in vitro studies have also demonstrated that it is possible to infect 
resting cells directly (Agosto et al., 2007; Plesa et al., 2007; Dai et al., 2009). 
In addition, a cytokine-rich environment and the presence of macrophages may play some 
roles in enhancing the formation of reservoir through some mechanisms (Eckstein et al., 
2001; Swingler et al., 2003). 
Another idea is that latently infected CD4+ T cells may originate from activated CD4+ T 
cells that return to a resting state after becoming infected. The fact that memory CD4+ T 
cells contribute the most to latently infected CD4+ T cells lends credence to this idea (Chun 
et al., 1997; Han et al., 2007).  
4.1 How to measure HIV-1 reservoirs 
The assay used in measuring latently infected cells was developed by Siliciano and Wong 
with their colleagues, and is referred to as the Infectious Units Per Million (IUPM) assay. 
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This assay involves the serial dilution and subsequent activation of resting CD4+ T cells 
from HIV-infected patients on HAART in the presence of allogeneic susceptible T blasts as 
targets to allow spreading infection (Finzi et al., 1997; Wong et al., 1997; Siliciano & Siliciano, 
2005). Determining the number of latently infected cells is made possible by enumerating 
the number of wells that demonstrate positive results for spreading infection under limiting 
dilution conditions. The IUPM assay, though costly and laborious, has proved highly 
invaluable for the characterisation of reservoir cells. Using this assay, latently infected cells 
are defined as cells that contain HIV DNA but do not produce infectious virions until they 
are stimulated to enter the cell cycle. Perhaps a better description is to define latent cells as 
those cells that contain integrated DNA that do not release virions until stimulated, if steps 
are taken to remove pre-integration complexes (Lassen et al., 2004a; Lassen et al., 2004b). 
Studies have shown that measurement of integrated HIV DNA is a useful surrogate marker 
of latently infected cells. However, studies that involved measuring latently infected cells 
over a period of time demonstrated constant level of both IUPM and integrated HIV DNA. 
This observation suggests that changes in the levels of integrated HIV DNA would be a 
good surrogate marker for changes in reservoir size (Brussel et al., 2003; Brussel et al., 2005; 
Koelsch et al., 2008; Chomont et al., 2009; Richman et al, 2009). 
The integration assay appears to be more sensitive and easier to perform than the IUPM 
assay, but the IUPM assay will best determine if any cells are capable of producing viable 
HIV particles. Some studies have demonstrated the superiority of integration assay over the 
IUPM assay. For instance, the levels of latently infected cells are so low in elite suppressors 
that the level is below the detection limit of the IUPM assay. However, a particular study 
detected integrated DNA in 10 out of 10 elite suppressor individuals (Blankson et al., 2007; 
Julg et al., 2010; Graf et al., 2011). The fact that a large fraction of integrated HIV proviruses 
are defective and contain a large number of mutations should be brought into consideration 
when using an integration assay as a surrogate marker for latently infected cells.  
5. How to purge latent HIV-1 reservoirs 
Most strategies for purging latent HIV-1 reservoirs involve the activation of latently infected 
cells to induce the expression of the integrated HIV-1  DNA making it susceptible to 
antiretroviral therapy and immune-mediated killing. Latently infected cells can be 
reactivated through a number of ways. One way is to up-regulate cellular transcription to 
induce HIV-1 gene expression. This involves inhibiting HDACs which promote latency by 
regulating genome structure and transcriptional activity. A study by Archin and colleagues 
demonstrated that synthetic HDAC inhibitors are capable of reactivating latently HIV-
infected cells in vitro (Archin et al., 2009). However, when HDAC inhibitor, HAART and 
valproic acid were co-administered, it gave mixed results (Lehrman et al., 2005; Blankson et 
al., 2007). Secondly, some interleukins have shown some promise in controlling latently 
infected cells. For instance, Chun and his colleagues demonstrated that patients treated with 
IL-2 plus HAART had fewer resting memory CD4+ T cells than patients who had HAART 
alone . The role of IL-7 in purging latently infected cells has also been tested in some studies 
with significant results. In addition, it is possible to purge latently infected cells by 
combining DNA methylation inhibitors with HAART, since DNA methylation is known to 
reduce intracellular transcriptional activity (Chun et al., 1999; Kauder et al., 2009). Prostratin 
has also been shown to up-regulate HIV-1 expression in peripheral blood mononuclear cells 
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from patients on HAART but down-regulates the expression of CD4 receptor; and another 
study has demonstrated that the transcription factor Est1 reactivates latent HIV-1 in resting 
memory T cells in patients who were on HAART without resulting to general activation of T 
cells (Kulkosky et al., 2001; Yang et al., 2009). 
Another method is to increase HIV-1 gene expression by altering the effects of non-coding 
cellular miRNAs. There are reports of cellular miRNAs contributing to HIV-1 latency in 
memory CD4+ T cells. When cellular miRNAs bind to the 3’ end of HIV-1 messenger RNA, 
they inhibit viral protein translation in cells resulting to the enhancement of latency. 
However, combination of the different activators may play a synergistic role in the 
reactivation of latent viral reservoirs as demonstrated by some studies. For instance, Reuse 
and colleagues have demonstrated that combining valproic acid and prostratin or 
suberoylanilide hydroxamic acid (SAHA)- an HDAC inhibitor- and prostratin more 
efficiently reactivated HIV-1 production in cell lines and cells isolated from patients 
receiving HAART than each compound alone (Reuse et al., 2009; Dahl et al., 2010). 
6. Conclusion 
Latent HIV-1 reservoirs are established early during primary infection in lymphocytes and 
macrophages and constitute a major barrier to eradication even in the presence of highly 
active antiretroviral therapy (Alcami et al., 2010). HAART reduces HIV-1 in plasma to 
undetectable levels, which led to the earlier idea that prolonged treatment might eradicate 
the infection. However, it was later discovered that HIV-1 can persist in a latent form in 
resting CD4+ T cells. In addition, both cellular and viral miRNAs could be involved in 
maintaining HIV-1 latency or in controlling low-ongoing viral replication. Identification of 
new cellular elements restricting the viral cycle provides a new paradigm on HIV-1 latency 
(Alcami et al., 2010).  It is obvious from growing evidence that HIV-1 eradication cannot be 
achieved without addressing the vicious circle of HIV-1 latency and reservoirs. Latently 
infected cells serve as a constant source of viral rebound even in the face of antiretroviral 
therapy. Finally, HIV-1 reservoirs and latency present monumental challenges to the 
scientific community, especially those involved in therapeutic research; and at the same time 
offer useful clues for eradication. 
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